Results 221 to 230 of about 9,662,184 (369)

Counting the Cost: The Hidden Financial Realities of Neuromuscular Disease Through Patient and Family Perspectives. [PDF]

open access: yesHealth Expect
Osman H   +13 more
europepmc   +1 more source

A scalable human iPSC-based neuromuscular disease model on suspended biobased elastomer nanofiber scaffolds. [PDF]

open access: yesBiofabrication, 2023
Cheesbrough A   +5 more
europepmc   +1 more source

Contribution of neuromuscular Impairment to physical functional Status in Patients with Lumbar Spinal Stenosis [PDF]

open access: yes, 1994
Fossel, Anne H.   +4 more
core  

Modelling Neuromuscular Diseases in the Age of Precision Medicine [PDF]

open access: gold, 2020
Alfina A. Speciale   +3 more
openalex   +1 more source

Skeletal Muscle Biomarkers of Amyotrophic Lateral Sclerosis: A Large‐Scale, Multi‐Cohort Proteomic Study

open access: yesAnnals of Neurology, EarlyView.
Objective Biomarkers with clear contexts of use are important tools for amyotrophic lateral sclerosis (ALS) therapy development. Understanding their longitudinal trajectory in the untreated state is key to their use as potential markers of pharmacodynamic response.
Oleksandr Dergai   +16 more
wiley   +1 more source

Genetic variability in the PLIN4 gene: A new sequence duplication causing autophagic vacuolar myopathy

open access: yesGenes and Diseases
Alessandra Carnazzi   +9 more
doaj   +1 more source

Profiling the TRPV4 ankyrin repeat domain interactome and its disruption by neuromuscular disease-causing mutations. [PDF]

open access: yesJ Biol Chem
Loder AK   +10 more
europepmc   +1 more source

Decrease of Muscle Mass in Young Patients With Neuromuscular Disease: Assessment of Sarcopenia. [PDF]

open access: yesJ Korean Med Sci, 2023
Kim J   +6 more
europepmc   +1 more source

Combination of Serum Neurofilament Light Chain and Serum Cardiac Troponin T as Biomarkers Improves Diagnostic Accuracy in Amyotrophic Lateral Sclerosis

open access: yesAnnals of Neurology, EarlyView.
Objective We aimed to evaluate the clinical utility of serum neurofilament light chain (sNfL) and cardiac troponin T (cTnT) in amyotrophic lateral sclerosis (ALS) and assess whether their combination improves diagnostic accuracy. Methods We retrospectively analyzed 293 ALS patients, 85 neurodegenerative disease controls, and 29 healthy controls.
Paula Lindenborn   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy